GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lexagene Holdings Inc (OTCPK:LXXGQ) » Definitions » Cash Flow from Financing

Lexagene Holdings (Lexagene Holdings) Cash Flow from Financing : $5.65 Mil (TTM As of Nov. 2022)


View and export this data going back to 2017. Start your Free Trial

What is Lexagene Holdings Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Nov. 2022, Lexagene Holdings paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.74 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.26 Mil on other financial activities. In all, Lexagene Holdings earned $1.00 Mil on financial activities for the three months ended in Nov. 2022.


Lexagene Holdings Cash Flow from Financing Historical Data

The historical data trend for Lexagene Holdings's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexagene Holdings Cash Flow from Financing Chart

Lexagene Holdings Annual Data
Trend Mar13 Mar14 Mar15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 4.21 8.14 15.48 4.60

Lexagene Holdings Quarterly Data
Feb18 May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.09 4.84 -0.11 -0.08 1.00

Lexagene Holdings Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Lexagene Holdings's Cash from Financing for the fiscal year that ended in Feb. 2022 is calculated as:

Lexagene Holdings's Cash from Financing for the quarter that ended in Nov. 2022 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Nov. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lexagene Holdings  (OTCPK:LXXGQ) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Lexagene Holdings's issuance of stock for the three months ended in Nov. 2022 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Lexagene Holdings's repurchase of stock for the three months ended in Nov. 2022 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Lexagene Holdings's net issuance of debt for the three months ended in Nov. 2022 was $0.74 Mil. Lexagene Holdings received $0.74 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Lexagene Holdings's net issuance of preferred for the three months ended in Nov. 2022 was $0.00 Mil. Lexagene Holdings paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Lexagene Holdings's cash flow for dividends for the three months ended in Nov. 2022 was $0.00 Mil. Lexagene Holdings received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Lexagene Holdings's other financing for the three months ended in Nov. 2022 was $0.26 Mil. Lexagene Holdings received $0.26 Mil on other financial activities.


Lexagene Holdings Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Lexagene Holdings's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Lexagene Holdings (Lexagene Holdings) Business Description

Traded in Other Exchanges
N/A
Address
500 Cummings Center, Suite 4550, Beverly, MA, USA, 01915
Lexagene Holdings Inc is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense. The MiQLab system delivers sensitivity, specificity, and breadth of detection and can return results in approximately two hours. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.

Lexagene Holdings (Lexagene Holdings) Headlines